Financial Disclosure Information Sample Clauses

Financial Disclosure Information. Sponsor shall (a) track and collect financial disclosure information from all “clinical investigators” involved in each Study and (b) prepare and submit the certification and/or disclosure of the same in accordance with all Applicable Law, including, but not limited to, Part 54 of Title 21 of the United States Code of Federal Regulations (Financial Disclosure by Clinical Investigators) and related FDA Guidance Documents. Sponsor shall track and collect from all “clinical investigators” involved in each Study one (1) “combined” certification and/or disclosure form for both Regeneron and Sponsor. For purposes of this Section 5.4, the term “clinical investigators” shall have the meaning set forth in Part 54.2(d) of Title 21 of the United States Code of Federal Regulations.
AutoNDA by SimpleDocs
Financial Disclosure Information. At Sponsor’s request, Site shall cause Principal Investigator and any sub-investigators to promptly provide to Sponsor (a) executed fi- nancial disclosure statements, in the form re- quired by Sponsor and (b) such other financial information as Sponsor may reasonably re- quest. During the term of the Trial and for a period of twelve (12) months thereafter, Site shall cause Principal Investigator and any sub- investigators to promptly notify Sponsor in writing of any changes thereto.
Financial Disclosure Information. At AstraZeneca’s request, the Principal Investigator shall promptly provide to AstraZeneca financial disclosure statements in compliance with 21 C.F.R. Part 54, in the form required by AstraZeneca and executed by the Principal Investigator and any sub-investigators and such other financial information as AstraZeneca may reasonably request. During the term of the Study and for a period of one (1) year thereafter, the Principal Investigator and any sub-investigators shall promptly notify AstraZeneca of any changes to such financial information.
Financial Disclosure Information. Provider shall cause Principal Investigator and any sub-investigators to promptly provide to Sponsor (a) executed financial disclosure statements, in the form required by Xxxxxxx and (b) such other financial information as Sponsor may reasonably request. During the term of the Study and for a period of 12 months thereafter, Provider shall cause Principal Investigator and any sub-investigators promptly to notify Sponsor in writing of any changes thereto.
Financial Disclosure Information. 6.1. The Parties shall work together to track and collect financial disclosure information from all “clinical investigators” involved in each Study.

Related to Financial Disclosure Information

  • Disclosure Information The disclosure of information as to the names and addresses of the Holders of Trust Securities in accordance with Section 312 of the Trust Indenture Act, regardless of the source from which such information was derived, shall not be deemed to be a violation of any existing law or any law hereafter enacted which does not specifically refer to Section 312 of the Trust Indenture Act, nor shall the Property Trustee be held accountable by reason of mailing any material pursuant to a request made under Section 312(b) of the Trust Indenture Act.

  • Financial Disclosure Contributions made to an XXX will be invested, at your election, in one or more of the regulated investment companies for which Xxxxxxxx Xxxxxx Capital Management serves as Investment Advisor or any other regulated investment company designated by Xxxxxxxx Funds. No part of the account(s) may be invested in life insurance contracts; further, the assets of the account(s) may not be commingled with other property. Information about the shares of each mutual fund available for investment by your account(s) must be furnished to you in the form of a prospectus governed by rules of the Securities and Exchange Commission. Please refer to the prospectus for detailed information concerning your mutual fund. You may obtain further information concerning IRAs and Xxxxxxxxx Education Savings Accounts from any District Office of the Internal Revenue Service. You can also obtain further information concerning IRAs by accessing IRS Publication 590 or Xxxxxxxxx Education Savings Accounts by accessing XXX Publication 970 on the IRS web site at xxxx://xxx.xxx.xxx. Fees and other expenses of maintaining the account(s) may be charged to you or the account(s). The current fee schedule is per account and shown below: Traditional, SEP, SIMPLE, and Xxxx XXX annual maintenance fee $15.00* Xxxxxxxxx Education Savings Account annual maintenance fee. $15.00* Transfer to successor trustee $25.00 Distribution to a participant (exclusive of systematic withdrawal plans) $25.00 Refund of excess contribution $25.00 Federal wire fee $15.00 Recharacterization $25.00 *capped at $30.00 per Social Security number. (An account is defined as an investment in a single regulated investment company within a Mutual Fund complex, regardless of whether your account number is the same for more than one fund.) If you decide not to prepay the annual maintenance fee, it will be deducted from your account(s) after September 15th of each year, and enough shares will be redeemed to cover the fee. The Custodian may change the fees payable in connection with the custodial account without prior notification. The method for computing and allocating annual earnings on your XXX will differ based on the investments chosen. Refer to the investment prospectus for the methods used for computing and allocating annual earnings. The growth in value of your XXX is neither guaranteed nor protected.

  • Financial Disclosures Each Spouse agrees that all financial disclosures of assets and liabilities have been exchanged amongst the Couple, if applicable in Section XIII. If the Couple has waived their rights to financial disclosures, then this sub-Section shall not apply to this Agreement. Each Spouse understands that if any financial disclosure has not been exchanged that it could render this Agreement void. Such financial disclosure shall be determined by an asset or liability equal to or more than the minimum legal limit in the state, or $5,000.00, whichever is greater in the total value at the time of signing this Agreement.

  • SEC Filings; Financial Statements; Information Provided (a) All forms, reports and other documents required to be filed by the Company with the SEC since January 1, 2001 (including those that the Company may file after the date hereof until the Closing) are referred to herein as the “Company SEC Reports.” Except as set forth in Section 3.4 of the Company Disclosure Schedule, the Company SEC Reports (i) were or will be filed on a timely basis and (ii) were or will be prepared in compliance in all material respects with the applicable requirements of the Securities Act, and the Exchange Act, as the case may be, applicable to such Company SEC Reports. None of the Company SEC Reports when filed, after giving effect to any amendments and supplements thereto filed prior to the date hereof, contained any untrue statement of a material fact or omitted to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. None of the Company’s Subsidiaries has filed, or is obligated to file, any forms, reports, schedules, statements or other documents with the SEC. As used in this Section 3.4(a), the term “filed” shall be broadly construed to include any manner in which a document or information is furnished, supplied or otherwise made available to the SEC. (b) Each of the consolidated financial statements (including, in each case, any related notes and schedules) contained or to be contained in the Company SEC Reports (i) complied or will comply as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto, (ii) were or will be prepared in accordance with generally accepted accounting principles (“GAAP”) applied on a consistent basis throughout the periods involved (except as may be indicated in the notes to such financial statements or, in the case of unaudited statements, as permitted by the SEC on Form 10-Q under the Exchange Act or for normal year-end adjustments) and (iii) fairly presented or will fairly present the financial position of the Company as of the dates thereof and the results of its operations and cash flows for the periods indicated, except that the unaudited interim financial statements were or are subject to normal and recurring year-end adjustments that have not been and are not expected to be material to the Company. The unaudited balance sheet of the Company as of June 30, 2004 is referred to herein as the “Company Balance Sheet.” (c) The information to be supplied by the Company for inclusion in the registration statement on Form S-4 pursuant to which the Company Series A Preferred Stock issued in the Merger and the Company Common Stock issuable upon conversion of the Company Series A Preferred Stock will be registered under the Securities Act (including any amendments or supplements, the “Registration Statement”), shall not at the time the Registration Statement is declared effective by the SEC contain any untrue statement of a material fact or omit to state any material fact required to be stated in the Registration Statement or necessary in order to make the statements in the Registration Statement not misleading. The information to be supplied by the Company for inclusion in the joint proxy statement/prospectus (the “Proxy Statement”) to be sent to the stockholders of the Company in connection with the meeting of the Company’s stockholders to consider the adoption of this Agreement and the Merger (the “Company Meeting”) and the Partners in connection with the Fund Consent Solicitation (as herein defined) shall not, on the date the Proxy Statement is first mailed to stockholders of the Company and the Partners, at the time of the Company Meeting and at the Effective Time, contain any statement which, at such time and in light of the circumstances under which it shall be made, is false or misleading with respect to any material fact, or omit to state any material fact necessary in order to make the statements made in the Proxy Statement not false or misleading; or omit to state any material fact necessary to correct any statement in any earlier communication with respect to the solicitation of proxies for the Company Meeting or the solicitation of consents in connection with the Fund Consent Solicitation which has become false or misleading. If at any time prior to the Effective Time any event relating to the Company, any Affiliate (as defined below) of the Company, or any officers or directors of any of them, should be discovered by the Company which should be set forth in an amendment to the Registration Statement or a supplement to the Proxy Statement, the Company shall promptly inform the Fund. As used in this Agreement, the term

  • Complete Information The Disclosure Information (as defined in Section 11.16) provided by WTC for inclusion in the Prospectus and the Preliminary Prospectus is true and accurate in all material respects. As of the Preliminary Prospectus Date and the Prospectus Date (a) there are no legal proceedings pending or known to be contemplated by governmental authorities against WTC or against any property of WTC, that would be material to the Noteholders, (b) WTC is not affiliated with any of the Affiliation Parties, and (c) there is no business relationship, agreement, arrangement, transaction or understanding between the Trustee and any of the Affiliation Parties that is entered into outside the ordinary course of business or is on terms other than would be obtained in an arm’s length transaction with an unrelated third party, apart from this transaction, that currently exists or that existed during the past two years and that is material to an investor’s understanding of the Notes.

  • Master Servicer’s Financial Statements and Related Information For each year this Agreement is in effect, the Master Servicer shall submit to the Trustee, any NIMS Insurer, each Rating Agency and the Depositor a copy of its annual unaudited financial statements on or prior to March 15 of each year, beginning March 15, 2006. Such financial statements shall include a balance sheet, income statement, statement of retained earnings, statement of additional paid-in capital, statement of changes in financial position and all related notes and schedules and shall be in comparative form, certified by a nationally recognized firm of Independent Accountants to the effect that such statements were examined and prepared in accordance with generally accepted accounting principles applied on a basis consistent with that of the preceding year.

  • Accurate Information All information heretofore, herein or hereafter supplied to Secured Party by or on behalf of Debtor with respect to the Collateral is and will be accurate and complete in all material respects.

  • Corporate Information Promptly upon, and in any event within five (5) Business Days after, becoming aware of any additional corporate or limited liability company information or division information of the type delivered pursuant to Section 6.01(f), or of any change to such information delivered on or prior to the Closing Date or pursuant to this Section 8.01 or otherwise under the Credit Documents, a certificate, certified to the extent of any change from a prior certification, from the secretary, assistant secretary, managing member or general partner of such Credit Party notifying the Administrative Agent of such information or change and attaching thereto any relevant documentation in connection therewith.

  • Factsheet Information General information entered into the higher education institutions’ profile and updated by the higher education institution. The general information about the institution is accessible to students. Autumn term [day/month] 04/30 Spring term [day/month] 09/30 Autumn term [day/month] 06/30 Spring term [day/month] 11/30 xxxxxxxx@xxxxxx.xxx.xx +000000000000 xxxxx://xxxxxxx.xxxxxx.xxx.xx/en Requirement Details Website Other Transcript xxxxx://xxxxxxx.xxxxxx.xxx.xx/page/Erasmus--Europe/How-to-Apply/82 2 Other Copy of Passport xxxxx://xxxxxxx.xxxxxx.xxx.xx/page/Erasmus--Europe/How-to-Apply/82 2 Other Learning Agreement xxxxx://xxxxxxx.xxxxxx.xxx.xx/page/Erasmus--Europe/How-to-Apply/82 2 Available infrastructure ad- justed for people with: Description of infras- tructure Contact details Website for information Infrastructure Not present xxxxx://xxxxxxx.xxxxxx.xxx.xx /en The institution will guide incoming mobile participants in finding accommodation, according to the requirements of the Erasmus Charter for Higher Education. Information and assistance can be provided by the following contact points and information sources: Contact email Contact phone Websites for information xxxxxxxx@xxxxxx.xxx.xx +000000000000 xxxxx://xxxxxxx.xxxxxx.xxx.xx/page/16/Accom modation/474 The institution will provide assistance, when required, in securing visas for incoming and outbound mobile partici- pants, according to the requirements of the Erasmus Charter for Higher Education. Information and assistance can be provided by the following contact points and information sources: Contact email Contact phone Websites for information xxxxxxxx@xxxxxx.xxx.xx +000000000000 xxxxx://xxxxxxx.xxxxxx.xxx.xx/page/16/Visa-an d-Residence-Permit/472 The institution will provide assistance in obtaining insurance for incoming and outbound mobile participants, accord- ing to the requirements of the Erasmus Charter for Higher Education. The receiving institution will inform mobile par- ticipants of cases in which insurance cover is not automatically provided. Information and assistance can be provided by the following contact points and information sources: Contact email Contact phone Websites for information xxxxxxxx@xxxxxx.xxx.xx +000000000000 xxxxx://xxxxxxx.xxxxxx.xxx.xx/page/16/Healt h-Insurance/473

  • Seller Information The Company may require each seller of Registrable Securities as to which any registration is being effected to furnish, and such seller shall furnish, to the Company such information regarding the distribution of such securities as the Company may from time to time reasonably request in writing.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!